Evidence map›Paper›PMID 40990233›Full record

SynthesisNeurodegenerative disease management2026

Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review.

Rabab Shami, Rania El Majzoub, Ali Ismail, Jana Kotaich, Mariam Kassem, Ghida Safadieh, Mohammad Fayyad-Kazan, Bahia Chahine

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neurodegenerative disease management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rabab ShamiNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Rania El MajzoubNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.ORCID 0009-0000-3045-057X
Ali IsmailNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Jana KotaichFaculty of Medical Sciences, Lebanese University, Lebanon.
Mariam KassemDepartment of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut, Lebanon.
Ghida SafadiehNeuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Mohammad Fayyad-KazanDepartment of Natural and Applied Sciences, School of Arts and Sciences, American University of Iraq - Baghdad, Baghdad, Iraq.
Bahia ChahineDepartment of Biomedical Sciences, School of Pharmacy, Lebanese International University, Mazraa, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study aims to systematically evaluate and synthesize preclinical evidence on the neuroprotective effects of Triptolide (Tri) in Alzheimer's disease (AD) models, focusing on its impact on amyloid-beta accumulation, synaptic dysfunction, neuroinflammation, oxidative stress, autophagy, and apoptosis.

introductionAD is the most common cause of dementia, yet current treatments largely target symptoms rather than underlying pathology. Tri, a bioactive compound from

methodsA systematic search of PubMed, Embase, and Web of Science was conducted up to 16 March 2024. English-language in vivo and in vitro studies on Tri's effects in AD models were included. Methodological quality was assessed using SYRCLE and SciRAP tools. The review is registered in PROSPERO (CRD42024521822).

resultsOut of 403 studies, 15 met the inclusion criteria (6 in vivo, 8 in vitro, 1 both). Tri reduced Aβ burden, enhanced memory and synaptic integrity, suppressed neuroinflammation and oxidative stress, and modulated autophagy and apoptosis.

conclusionTri demonstrates significant multi-target neuroprotective effects in AD preclinical models. Further high-quality studies are warranted to optimize dosing, delivery, and safety for clinical translation.

Indexed as

Alzheimer DiseaseDiterpenesNeuroprotective AgentsPhenanthrenesAmyloid beta-PeptidesAnimalsApoptosisAutophagyDisease Models, AnimalDisease ProgressionEpoxy CompoundsHumansOxidative StressAmyloid beta-PeptidesDiterpenesEpoxy CompoundsNeuroprotective AgentsPhenanthrenestriptolideAD cell cultureAD miceAlzheimer’s diseaseneurodegenerative diseasetriptolide treatment

Identifiers

PMID40990233
PMCPMC13011600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.